Sector Gamma AS acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 89,964 shares of the biopharmaceutical company’s stock, valued at approximately $8,811,000. Alexion Pharmaceuticals makes up about 1.5% of Sector Gamma AS’s portfolio, making the stock its 25th biggest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $28,000. Redhawk Wealth Advisors Inc. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $29,000. Investors Research Corp lifted its position in Alexion Pharmaceuticals by 52.0% during the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 104 shares in the last quarter. Ossiam bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $32,000. Finally, Capital Bank & Trust Co lifted its position in Alexion Pharmaceuticals by 355.9% during the 2nd quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 210 shares in the last quarter. 94.68% of the stock is currently owned by institutional investors and hedge funds.

ALXN has been the topic of several analyst reports. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 15th. Citigroup set a $150.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 30th. Royal Bank of Canada reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. Piper Jaffray Companies set a $180.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. Finally, Bank of America initiated coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, October 17th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $159.00.

Shares of Alexion Pharmaceuticals stock traded up $2.74 during trading on Friday, hitting $110.79. 1,255,600 shares of the stock were exchanged, compared to its average volume of 1,803,421. The stock has a market capitalization of $23.73 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 1.02 and a beta of 1.65. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average price of $102.45 and a 200-day moving average price of $115.69. Alexion Pharmaceuticals, Inc. has a 1-year low of $92.56 and a 1-year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.47 by $0.32. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 EPS. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 9.41 EPS for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What is quantitative easing?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.